Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $20.37 USD
Change Today +0.15 / 0.74%
Volume 519.3K
MNTA On Other Exchanges
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

momenta pharmaceuticals inc (MNTA) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/19/15 - $25.56
52 Week Low
10/13/14 - $9.38
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

momenta pharmaceuticals inc (MNTA) Related Businessweek News

No Related Businessweek News Found

momenta pharmaceuticals inc (MNTA) Details

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases. The company’s complex generics programs comprise Enoxaparin sodium injection, a generic version of Lovenox that is used for the prevention and treatment of deep vein thrombosis, and to support the treatment of acute coronary syndromes; and M356, a generic version of Copaxone, which is a complex drug consisting of a synthetic mixture of polypeptide chains for the treatment of patients with relapsing-remitting multiple sclerosis. Its biosimilars programs include M923, a biosimilar for rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis; M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis; and other biosimilar programs. The company’s novel products comprise M402, a novel oncology drug candidate that is in a Phase 2 clinical study derived from heparin; hsIVIg program, a hyper-sialylated version of intravenous immunoglobulin; SIF3 program, a novel recombinant protein containing three IgG Fc regions joined to maximize activity; and Anti-FcRn program for acute and chronic/intermittent therapies in a range of autoantibody driven diseases. It has collaboration and license agreements with Sandoz AG; Baxter International, Inc.; Baxter Healthcare Corporation; and Baxter Healthcare SA. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

256 Employees
Last Reported Date: 02/27/15
Founded in 2001

momenta pharmaceuticals inc (MNTA) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $643.4K
Co-Founder, Chief Scientific Officer and Seni...
Total Annual Compensation: $400.7K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $374.8K
Senior Vice President and President of Biosim...
Total Annual Compensation: $19.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $410.0K
Compensation as of Fiscal Year 2014.

momenta pharmaceuticals inc (MNTA) Key Developments

Momenta Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Second Half of 2015

Momenta Pharmaceuticals Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported product revenues of USD 19.305 million compared to USD 5.690 million a year ago. Operating loss was USD 2.412 million compared to USD 26.358 million a year ago. Net loss was USD 2.222 million compared to USD 26.156 million a year ago. Basic and diluted loss per share was USD 0.04 compared to USD 0.51 a year ago. The smaller net loss is primarily due to the milestone payments and product revenue earned from the approval and subsequent launch of Glatopa, offset by an increase in operating expenses. For the six months, the company reported product revenues of USD 22.027 million compared to USD 10.502 million a year ago. Operating loss was USD 24.489 million compared to USD 53.982 million a year ago. Net loss was USD 24.099 million compared to USD 53.518 million a year ago. Basic and diluted loss per share was USD 0.41 compared to USD 1.04 a year ago. The company provided guidance that it expects its operating expenses, excluding stock-based compensation and net of collaborative revenues, to be approximately USD 36 to USD 40 million per quarter for the second half of 2015.

Momenta Pharmaceuticals Inc. to Report Q2, 2015 Results on Aug 04, 2015

Momenta Pharmaceuticals Inc. announced that they will report Q2, 2015 results at 10:00 AM, US Eastern Standard Time on Aug 04, 2015

Momenta Pharmaceuticals Inc., Q2 2015 Earnings Call, Aug 04, 2015

Momenta Pharmaceuticals Inc., Q2 2015 Earnings Call, Aug 04, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNTA:US $20.37 USD +0.15

MNTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amarin Corp PLC $2.23 USD +0.14
OraSure Technologies Inc $5.37 USD +0.12
SciClone Pharmaceuticals Inc $7.79 USD +0.01
Spectrum Pharmaceuticals Inc $7.60 USD +0.11
Sucampo Pharmaceuticals Inc $28.28 USD +0.36
View Industry Companies

Industry Analysis


Industry Average

Valuation MNTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.9x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MOMENTA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at